Resumen

COLMENARES, Ana. Controversias en el manejo de la talla baja idiopática. Rev. Venez. Endocrinol. Metab. [online]. 2015, vol.13, n.1, pp.4-13. ISSN 1690-3110.

Idiopathic short stature (ISS) is an exclusion diagnostic which includes a broad and heterogeneous group of supposedly healthy children with height below -2 standard deviations. In the United States, treatment with growth hormone (GH) is approved for children with ISS, as opposed to the majority of European countries. The final height of children with ISS whom are treated with GH is highly variable and dependent on multiples factors at the beginning and during the treatment. For this reason, the indication of GH therapy in ISS children is not consensual. This revision contains actual data about the most recently published studies in patients with ISS treated with GH until final height, associated factors to height gaining, metabolic, psychosocial and adverse events, and finally, other therapeutic options such as GH combined with GnRH analogues, aromatase inhibitors and recombinant human IGF1.

Palabras clave : Idiopathic short stature; familial short stature; growth hormone treatment; final height.

        · resumen en Español     · texto en Español     · Español ( pdf )